Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and the AddPro Group in connection with the acquisition of IT Advisor Sweden AB and refinancing
Mandate

Vinge advises Axcel VI and the AddPro Group in connection with the acquisition of IT Advisor Sweden AB and refinancing

June 02, 2021 Banking and Finance M&A Corporate Crime & Compliance Employment and Benefits IT, Telecommunications and Outsourcing Commercial Agreements

IT Advisor Sweden AB provides consultancy services and product-related services for IT-security. The company is located in Stockholm and has currently 26 employees with customers in Sweden, Norway, Finland and Denmark.

The AddPro Group has also, in connection with the acquisition of IT Advisor Sweden AB, made a refinancing of outstanding credit facilities.

Vinge’s team consisted of partners Christina Kokko (M&A) and Mikael Ståhl (Banking & Finance) together with Johanna Wiberg, Stina Bengtsson and Gustav Persson (M&A), Pauline Lagerstrand, Karl-Gustaw Tobola, Nina Gransäter (Banking & Finance), Emil Lindvall (Employment), Christoffer Nordin (Commercial agreements), Fredrika Hjelmberg (IT & GDPR) and Tove Lövgren Frisk (Compliance).

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025